This article is more than 5 years old. Information may no longer be current.

FDA stops Amgen's pediatric trials of Sensipar

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Food and Drug Administration has halted Amgen Inc.'s pediatric clinical trials of the kidney drug Sensipar (cinacalcet hydrochloride) after a 14-year-old patient died. Sensipar is used as a hyperparathyroidism treatment for adults with chronic kidney disease on dialysis. The drug was being tested in children younger than 18 years old. The FDA said it has not yet concluded whether or not Sensipar had a role in the patient's death.

(The outlook for Amgen)

"Amgen is working as rapidly as possible to understand the circumstances of what happened," Ashleigh Koss, a spokeswoman for the Amgen told Bloomberg. "This analysis is ongoing and will be concluded as quickly as possible."